drugset / Trial / NCT06173895

A Relative Bioavailability Study of LY3454738 in Healthy Participants

NCT06173895 ↗

Phase 1 Completed 30 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelBasic science

Summary

The main purpose of this study is to look at the amount of the study drug, LY3454738 that gets into the blood stream and how long it takes the body to get rid of it when given under the skin comparing a test formulation versus a reference formulation in healthy participants. The study will also evaluate the safety and tolerability of LY3454738 and information about any side effects experienced will be collected. For each participant, the total duration of the study will be approximately up to 17 weeks, including screening period.

Timeline

Start
2024-01-12
Primary completion
2024-05-02
Completion
2024-05-02

Drugs

EvaluationDrugModalityDoseRoute
Subject UCENPRUBART Monoclonal antibody — Subcutaneous

Indications

No indication recorded.